New York, Jan 8, 2026, 20:57 (ET) — Market closed
- U.S. House panels invited CEOs of UnitedHealth and four other insurers to testify on coverage affordability on Jan. 22
- UnitedHealth shares closed up 1.5% at $346.85; traders eye key chart levels into Friday’s session
- Wolfe Research lifted its price target to $400; investors look ahead to UnitedHealth’s Jan. 27 results and 2026 guidance
U.S. House lawmakers have called on UnitedHealth Group Incorporated (UNH.N) and four other major insurers to testify on coverage affordability later this month, signaling growing Washington scrutiny. UnitedHealth shares rose 1.5% to close at $346.85 on Thursday. The House Energy and Commerce Committee and the Ways and Means Committee extended invitations to UnitedHealth, CVS Health, Cigna, Elevance and Ascendia for testimony on Jan. 22.
The timing is sensitive. Congress is once again locked in a dispute over subsidies under the Affordable Care Act, known as Obamacare, a debate that could influence investor risk assessments for insurers facing regulatory scrutiny. Separately, two senators accused UnitedHealth of withholding internal documents related to an investigation into its nursing home care program, the Guardian reported.
The broader market offered little support. Wall Street closed mixed on Thursday as traders awaited Friday’s December nonfarm payrolls report, which could influence rate outlooks and defensive sectors, Reuters reported. “It’s become a ‘show me’ sector,” said Art Hogan, chief market strategist at B. Riley Wealth, noting that investors now demand proof after a string of costly bets. Reuters
Wolfe Research increased its price target for UnitedHealth to $400 from $375 and kept its Outperform rating, according to an MT Newswires report published by MarketScreener.
UNH shares are trading near key technical levels, attracting investor attention amid active news. The stock’s 200-day moving average is around $346, a key indicator of its longer-term trend, while the 50-day average stands near $331. According to Yahoo Finance data, the 52-week range spans $234.60 to $606.36, with the stock down roughly 34% over that period.
UnitedHealth is scheduled to report full-year 2025 earnings and issue 2026 guidance on Tuesday, Jan. 27, before markets open. The company will hold a conference call at 8 a.m. ET. Investors will watch for updates on cost and pricing assumptions in a challenging policy climate.
The company has been working to recover after cost pressures last year hit confidence. In May, UnitedHealth paused its 2025 forecast and swapped CEO Andrew Witty for former chief executive Stephen Hemsley, Reuters reported at the time.
The path is uncertain. Difficult hearings often trigger market reactions — more questions, soundbites, and renewed talks of rule changes. The Senate document dispute adds a factor investors might hold back from including in earnings reports.
On Friday, traders will focus on the jobs report to gauge its impact on yields. UnitedHealth is scheduled to testify on Jan. 22, with earnings and 2026 guidance expected on Jan. 27.
